Chromium & Cardiovascular Disease
In studies dating back as far as 1966, scientists have consistently demonstrated the effects of chromium on blood-fat metabolism in humans; and according to a 2002 scientific presentation by researchers at Harvard School of Public Health, "functional chromium deficiency in people with cardiovascular disease may be directly related to a relative lack of chromium in the diet."
Chromium Picolinate Formula Lowers CVD Risk In Type II Diabetics.
WASHINGTON-Chromium picolinate formulated with biotin lowers cardiovascular disease (CVD) risk factors in Type II diabetics, according to research presented at the American Heart Association's sixth Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, held here.
In the randomized double blind, placebo-controlled, multi-centre study, 368 Type II diabetes patients received a placebo or chromium picolinate and biotin for 12 weeks. Non-high-density lipoprotein (HDL) cholesterol was significantly lowered (by 14 mg/dL) in Type II diabetes patients already receiving statin therapy or other cholesterol-lowering prophylaxes, compared to the placebo group. In addition, test subjects who took Diachrome had significantly lower triglyceride levels (225 mg/dL) compared to individuals in the placebo group (278 mg/dL).
"These results are impressive since glucose lowering medications do not commonly reduce bad cholesterol levels, and frequently raise them as a side effect," said Cesar Albarracin, M.D., lead researcher. "The findings from this study suggest that Diachrome can serve as a safe and effective adjunct therapy to diet and prescription medications in lowering both blood glucose and cholesterol levels."
The authors conducted two concomitant studies that examined the effects of a behaviour modification plan (BMP) that included the use of nutritional supplements (one group received 400 mcg of chromium as chromium picolinate [CP]) and which collected pre- and post-study serum cholesterol measurements.
The results from the CP-supplemented group indicate that "chromium picolinate can facilitate reductions in triglycerides (TC) and LDL serum cholesterol," especially in people whose baseline TC levels were above 200 mg/dL.
In this study, 28 people were given either 200 mcg of chromium as chromium picolinate (CP) or a placebo, daily, for 42 days in this double-blind crossover study. In this trial, of the patients supplemented with CP, four of the six most important serum lipid (circulating blood fats) were beneficially altered during the test period.
Specifically, levels of total cholesterol, LDL (or "bad") cholesterol and its transport protein, apolipoprotein B, were all beneficially decreased, while levels of the transport protein for HDL (or "good") cholesterol, apolipoprotein A, were beneficially increased.
The authors say that "Because each of these variables is related […] to the development of coronary artery disease, chromium picolinate is an excellent agent to consider in the treatment and prevention of hyperlipidemia."